Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

VictorMason Oct. 4 at 4:34 PM

$RLMD someone said there was bad news about one of their phase 3s but cant find anything?

1 · Reply

ibaian Oct. 4 at 4:09 PM

$RLMD posted on 30th August

0 · Reply

SEC_LIARS Oct. 4 at 9:50 AM

$RLMD My target price was $2.70, and although my average cost went up a bit during the month-long consolidation because I added more shares, I made about $66,000 from swing trading over just a little more than a month — despite all the distractions along the way. I hope everyone takes profit well at your own target prices. Good luck.

0 · Reply

SweepCastApp Oct. 4 at 4:12 AM

$RLMD: Unusual Options Activity Alerted CALL flow observed 769x contracts at Strike price of $2 Exp on 11/21/2025 with Premium of $38K and showing BULLISH Sentiment

0 · Reply

teaman60 Oct. 4 at 1:01 AM

$RLMD Made good money on this but the fact that they don't have the cash to last a year is difficult to ignore

0 · Reply

cholle Oct. 3 at 11:59 PM

$RLMD +27.15%

0 · Reply

TraderJay85 Oct. 3 at 8:23 PM

$ZTEK broke even 🤷‍♂️ $POET small loss 7 cents 👎 $RLMD break even 🤷‍♂️ $SLSN small loss 8 cent 👎 Had 10 Big wins, 5 tiny losses, and 3 still holding, from last nights PMM'S list. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER.

0 · Reply

Gashcooper Oct. 3 at 6:31 PM

$RLMD 😌

1 · Reply

botanist Oct. 3 at 5:19 PM

$RLMD dipping a bit harder than expected…

1 · Reply

_www_larval_com_ Oct. 3 at 5:12 PM

$RLMD just slipped -5% lower to -17% (~675Kv) a few minutes ago, 10/17 options, follow for more volatility.

0 · Reply

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 24 days ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 8, 2025, 1:55 PM EDT - 2 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 2 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 2 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 3 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 3 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 10:02 PM EDT - 5 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 5 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 5 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 1:38 PM EDT - 5 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 5 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 5 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 6 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 8:07 PM EDT - 6 months ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 6 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 6 months ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 6 months ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 8 months ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 10 months ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 10 months ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 2:02 PM EST - 10 months ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 8:00 AM EST - 10 months ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 10 months ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 11 months ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 14, 2024, 7:30 AM EST - 11 months ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 10, 2024, 9:39 AM EST - 11 months ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:32 PM EST - 11 months ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 11 months ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 19, 2024, 5:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Jul 18, 2024, 5:15 PM EDT - 1 year ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Jul 17, 2024, 3:30 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

Jul 16, 2024, 3:45 PM EDT - 1 year ago

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Jul 15, 2024, 3:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Jul 13, 2024, 7:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

Jul 12, 2024, 6:45 PM EDT - 1 year ago

Potential Securities Violations By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate Dialogue

Jul 11, 2024, 2:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Scrutiny By The Schall Law Firm For Potential Securities Breaches Urging Affected Investors To Initiate Conversation

Jul 10, 2024, 2:30 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Impacted Investors Are Urged To Establish Dialogue

Jul 9, 2024, 3:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Being Probed By The Schall Law Firm For Potential Securities Breaches And Affected Investors Are Encouraged To Set Up Communication

Jul 8, 2024, 1:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Impacted Investors Are Urged To Establish Communication

Jul 7, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Begins Probe Into Relmada Therapeutics Inc For Suspected Securities Violations And Promotes Investors With Losses To Get In Touch

Jul 6, 2024, 11:00 AM EDT - 1 year ago

Investigation Into Possible Securities Infringements By Relmada Therapeutics Inc Is Being Conducted By The Schall Law Firm And It Invites Affected Investors To Reach Out

Jul 5, 2024, 4:00 PM EDT - 1 year ago

The Schall Law Firm Initiates Examination Into Relmada Therapeutics Inc For Potential Securities Breaches And Encourages Impacted Investors To Establish Contact

VictorMason Oct. 4 at 4:34 PM

$RLMD someone said there was bad news about one of their phase 3s but cant find anything?

1 · Reply

ibaian Oct. 4 at 4:09 PM

$RLMD posted on 30th August

0 · Reply

SEC_LIARS Oct. 4 at 9:50 AM

0 · Reply

SweepCastApp Oct. 4 at 4:12 AM

$RLMD: Unusual Options Activity Alerted CALL flow observed 769x contracts at Strike price of $2 Exp on 11/21/2025 with Premium of $38K and showing BULLISH Sentiment

0 · Reply

teaman60 Oct. 4 at 1:01 AM

$RLMD Made good money on this but the fact that they don't have the cash to last a year is difficult to ignore

0 · Reply

cholle Oct. 3 at 11:59 PM

$RLMD +27.15%

0 · Reply

TraderJay85 Oct. 3 at 8:23 PM

0 · Reply

Gashcooper Oct. 3 at 6:31 PM

$RLMD 😌

1 · Reply

botanist Oct. 3 at 5:19 PM

$RLMD dipping a bit harder than expected…

1 · Reply

_www_larval_com_ Oct. 3 at 5:12 PM

$RLMD just slipped -5% lower to -17% (~675Kv) a few minutes ago, 10/17 options, follow for more volatility.

0 · Reply

TheGodsMustBeCrazy Oct. 3 at 4:52 PM

@teaman60, you predicted $RLMD would be <0.20/share (screenshot below). Now it's 2.35/share, i.e. 1100% higher than your wise prediction. YOU.ARE.A.CLOWN.🤡

1 · Reply

Vikingsstrade Oct. 3 at 4:23 PM

$RLMD $OLMA $WYFI $MRUS Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

teaman60 Oct. 3 at 3:57 PM

$RLMD GidsMustBeCrazy, where are u lol

0 · Reply

teaman60 Oct. 3 at 3:55 PM

$RLMD The selling isn't over yet. It's being systematicaly dumped

0 · Reply

teaman60 Oct. 3 at 2:45 PM

$RLMD Looks like someone dumped at least 21,000 shares in first 30 mins. This is a typical Friday for a P&D

0 · Reply

teaman60 Oct. 3 at 2:37 PM

$RLMD Now u will see the Pumpers dissappear

0 · Reply

botanist Oct. 3 at 2:07 PM

$RLMD here’s the day to add

0 · Reply

teaman60 Oct. 3 at 1:56 PM

$RLMD There it is

0 · Reply

teaman60 Oct. 3 at 1:36 PM

$RLMD Need a or drop

1 · Reply

makingitnow Oct. 3 at 1:11 PM

$RLMD We need to push here. Lets Go!

1 · Reply

ash1012 Oct. 3 at 1:10 PM

$RLMD can we break $3.00 today ?

1 · Reply

SadyK189 Oct. 3 at 3:11 AM

$RLMD Next key level to test is 3.4 - 3.75. Currently at 2.75

1 · Reply

Market Cap	88.29M
Revenue (ttm)	0.00
Net Income (ttm)	-79.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	973,200
Avg Vol	869,396
Day's Range	N/A - N/A
Shares Out	33.19M
Stochastic %K	60%
Beta	0.91
Analysts	Hold
Price Target	$1.00